Reata Pharmaceuticals Intrinsic Value Calculation – REATA PHARMACEUTICALS Reports Second Quarter Earnings Results for FY2023

August 25, 2023

🌥️Earnings Overview

On August 8 2023, REATA PHARMACEUTICALS ($NASDAQ:RETA) reported their fiscal year 2023 second quarter earnings, ending on June 30 2023. The company saw a substantial increase in revenue from the same period last year, reporting total revenue of USD 22.8 million compared to 0.8 million last year. Net income was also significantly improved, from -73.6 million to 193.0 million.

Stock Price

On Tuesday, REATA PHARMACEUTICALS reported their second quarter earnings results for the fiscal year 2023. The stock opened at $166.7 and closed at $167.2, representing a 0.4% increase from the closing price of 166.4 the day before.

Additionally, operating expenses were down by 4%, due mainly to cost-saving initiatives put in place by the company in the quarter. Overall, REATA PHARMACEUTICALS reported a solid performance in the second quarter of 2023 and the stock price increase confirms investor confidence in the success of the company going forward. As they continue to develop new drugs and expand their existing portfolio of medicines, REATA PHARMACEUTICALS is well-positioned to continue delivering strong financial results in the future. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Reata Pharmaceuticals. More…

    Total Revenues Net Income Net Margin
    23.48 -87.62 -1585.3%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Reata Pharmaceuticals. More…

    Operations Investing Financing
    -248.34 59.42 90.61
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Reata Pharmaceuticals. More…

    Total Assets Total Liabilities Book Value Per Share
    502.59 415.3 2.31
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Reata Pharmaceuticals are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    15.2% -200.4%
    FCF Margin ROE ROA
    -1062.4% 135.6% -5.9%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Reata Pharmaceuticals Intrinsic Value Calculation

    GoodWhale has conducted an analysis of REATA PHARMACEUTICALS‘ wellbeing and based on our proprietary Valuation Line, the intrinsic value of REATA PHARMACEUTICALS share is approximately $230.0. As of the current market rate, REATA PHARMACEUTICALS stock is being traded at $167.2 which is undervalued by 27.3%. This presents a great opportunity for investors to purchase REATA PHARMACEUTICALS stock and benefit from potential future appreciation. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company’s lead product candidate, bardoxolone methyl, is in clinical development for the treatment of rare and orphan diseases, including Friedreich’s ataxia, alpha-1 antitrypsin deficiency, and motor neuron disease. Reata’s other product candidates include omaveloxolone, a small molecule activator of Nrf2, which is in clinical development for the treatment of Friedreich’s ataxia, and RTA 408, an oral antioxidant, which is in clinical development for the treatment of chronic kidney disease. Reata’s competitors in the rare and orphan disease space include Aravive Inc, Seelos Therapeutics Inc, and HilleVax Inc.

    – Aravive Inc ($NASDAQ:ARAV)

    Aravive, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company focuses on the discovery and development of therapeutic candidates to target cancer stem cells and tumor microenvironment for the treatment of cancer.

    – Seelos Therapeutics Inc ($NASDAQ:SEEL)

    Seelos Therapeutics Inc is a clinical stage biopharmaceutical company. The company focuses on the development of central nervous system disorders. Seelos Therapeutics Inc has a market cap of 94.97M as of 2022, a Return on Equity of -127.52%. The company’s current lead product candidate is SLS-002, which is in Phase 2 clinical trials for the treatment of post-traumatic stress disorder.


    This was an impressive turnaround for investors, providing them with confidence in the company’s ability to drive growth and profitability. Investors should remain positive on the stock, as the performance of the company appears to be improving significantly. Analysts should continue to closely monitor REATA Pharmaceuticals for future developments as they work to achieve sustainable success.

    Recent Posts

    Leave a Comment